达拉菲尼治疗皮肤黑色素瘤的效果及其对垂体同源框1蛋白表达的影响  

Effects of dabrafenib in treatment of skin melanoma and its influence on the expression of pituitary homeobox 1 protein

作　　者：汪娟[1] 陈涛[1] Wang Juan;Chen Tao(Department of Pharmacy,Wuhan First Hospital,Wuhan 430000,China)

机构地区：[1]武汉市第一医院药学部,武汉430000

出　　处：《肿瘤研究与临床》2022年第2期116-119,共4页Cancer Research and Clinic

摘　　要：目的:探讨达拉菲尼治疗皮肤黑色素瘤(CMM)的效果及其对垂体同源框1(PITX1)蛋白表达的影响。方法:选取武汉市第一医院2016年11月至2017年12月收治的86例CMM患者为研究对象,采用随机数字表法分为观察组和对照组各43例,对照组行化疗,观察组在对照组化疗方案基础上加用达拉菲尼。采用免疫组织化学法检测两组患者PITX1蛋白表达情况。比较两组治疗效果、复发率、生存情况、PITX1阳性表达率及不良反应发生情况。结果:观察组治疗有效率高于对照组[46.51%(20/43)比25.58%(11/43)],差异有统计学意义( χ^(2)=3.23, P=0.043);观察组疾病控制率高于对照组[93.02%(40/43)比72.09%(31/43)],差异有统计学意义( χ^(2)=5.17, P=0.023)。与对照组比较,观察组总生存、无进展生存均更好,复发率更低,PITX1阳性表达率更高(均 P<0.05)。观察组不良反应发生率低于对照组[11.63%(5/43)比32.56%(14/43)],差异有统计学意义( χ^(2)=5.47, P<0.05)。 结论:达拉菲尼治疗CMM效果较好,可提高PITX1蛋白表达水平,降低复发率及不良反应发生率,并延长患者生存时间。Objective To investigate the therapeutic effect of dabrafenib in treatment of cutaneous melanoma(CMM)and its influence on the expression of pituitary homeobox 1(PITX1)protein.Methods A total of 86 patients with CMM admitted to Wuhan First Hospital from November 2016 to December 2017 were selected as the research objects,and all patients were divided into the observation group and the control group according to random number table,43 cases in each group.The control group received chemotherapy regimen,and the observation group was added with dabrafenib on the basis of the control group.Immunohistochemistry method was used to detect the expressions of PITX1 protein in both groups.The treatment effect,recurrence rate,survival,PITX1 expression positive rate and adverse reactions were compared between the two groups.Results The treatment effective rate in the observation group was higher than that in the control group[46.51%(20/43)vs.25.58%(11/43)],and the difference was statistically significant(χ^(2)=3.23,P=0.043);the disease control rate in the observation group was higher than that in the control group[93.02%(40/43)vs.72.09%(31/43)],and the difference was statistically significant(χ^(2)=5.17,P=0.023).Compared with the control group,the observation group had better overall survival and progression-free survival,lower recurrence rate,and higher PITX1 positive rate(all P<0.05);adverse reaction rate in the observation group was lower than that in the control group[11.63%(5/43)vs.32.56%(14/43)],and the difference was statistically significant(χ^(2)=5.47,P<0.05).Conclusions Dabrafenib has a better effect in the treatment of CMM,which can increase the expression level of PITX1,reduce the recurrence rate and the incidence of adverse reactions,and prolong the survival time of patients.

关 键 词：黑色素瘤 垂体同源框1 达拉菲尼 治疗效果 预后 

分 类 号：R739.5[医药卫生—肿瘤]